Tango Therapeutics, Inc. (TNGX) earnings date
Mar 15, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | before open | 40 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | before open | 42 | 8-K |
| Q1 FY2026 | Wed, May 13, 2026 | after close | 43 | 8-K |
| Q4 FY2025 | Thu, Mar 5, 2026 | before open | 64 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | before open | 35 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | before open | 36 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | before open | 42 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L pancreatic cancer; combination was generally well-tolerated at go-forward dose Registrational Phase 3 study of vopimetostat plus daraxonrasib as front-line treatment for patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027 Data from vopimetostat monotherapy in non-small cell lung cancer (NSCLC) and brain-penetrant TNG456 in NSCLC, " exhibit |
| Q3 FY2026 | "As of September 30, 2026, the Company held $977.5 million in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan." exhibit |
| Q2 FY2026 | "Initiate Phase 1/2 vopimetostat + ERAS-0015 (Erasca) combination study in 2H 2026 Financial Results As of June 30, 2026, the Company held $1.0 billion in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TNGX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TNGX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TNGX/"><img src="https://veritasdata.dev/embed/TNGX.svg" alt="TNGX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TNGX/)
Script
<script async src="https://veritasdata.dev/embed/TNGX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TNGX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.